Carsten Utoft Niemann

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

Kirsten Fischer, Othman Al‐Sawaf, Jasmin Bahlo et al. · New England Journal of Medicine · 2019 · 852 citations

Pharmacy, Pharmacology, Pharmacotherapy +14

Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Barbara Eichhorst, Tadeusz Robak, Emili Montserrat et al. · Annals of Oncology · 2020 · 568 citations · Full text

Medicine, Hematology, Immunology +14

TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy

Christian Winther Eskelund, Christina Dahl, Jakob Werner Hansen et al. · Blood · 2017 · 396 citations · Full text

Medicine, Hematology, Oncology +14

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial

Mohammed Farooqui, Janet Valdez, Sabrina Martyr et al. · The Lancet Oncology · 2014 · 366 citations · Full text

Medicine, Immunology, Oncology +11

Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial

Othman Al‐Sawaf, Can Zhang, Maneesh Tandon et al. · The Lancet Oncology · 2020 · 327 citations

Medicine, Hematology, Immunology +15